Research programme: adenovirus infection therapeutics - AiCuris
Latest Information Update: 08 Sep 2016
At a glance
- Originator AiCuris
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Adenovirus infections
Most Recent Events
- 07 Sep 2016 Early research in Adenovirus infections in Germany before September 2016 (AiCuris pipeline, September 2016)